An open study on the pharmacokinetics and safety of oral voriconazole in adult patients with cystic fibrosis
Read time: 1 mins
Last updated:28th Mar 2007
The primary endpoints of the trial are to determine the pharmacokinetic parameters for oral voriconazole and to determine if voriconazole serum levels >1.0mg L-1 are achieved in adult patients with cystic fibrosis using a standard oral dosing regimen.
|Study start date||2007-03-28|